The transcription factors ISL-1 and MAFA, but not NKX6-1 Characterize a Stem-cell Derived Population of Endocrine Pancreatic Cells Capable of Controlling blood Glucose in Rodent Models of Diabetes.
Ratiu J, Southard SM, et al., 2023. The transcription factors ISL-1 and MAFA, but not NKX6-1 Characterize a Stem-cell Derived Population of Endocrine Pancreatic Cells Capable of Controlling blood Glucose in Rodent Models of Diabetes. Medical Research Archives 11i12.4797 (2023)
About Seraxis, Inc.
Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.
